Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

1

Biologic therapy significantly reduces the risk of ocular surface diseases in psoriasis patients compared to nonbiologic systemic therapy.
2

The study analyzed data from over 30,000 patients on biologics and 35,000 on nonbiologics, assessing 68 ocular outcomes.
3

Strongest benefits of biologic therapy were observed for dry eye disease, keratitis, and conjunctivitis, with effects lasting up to 10 years.
4

Regional analyses indicated lower risks for certain conditions, such as age-related macular degeneration, particularly in the US.
5

The observational nature of the study limits causation claims, and potential biases and misclassifications were noted.

1